Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial still showed an encouraging signal in the reduction in the relative risk of progression to severe disease or death within 35 days. Says that it performed a post hoc analysis on groups of patients recognised to be at greater risk of developing severe disease in hospital, to assess the strength of this signal. Says that the analyses showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. Says SNG001 significantly reduced the risk of progression to severe disease and death compared to a placebo by 70% in the per-protocol population.

SNG001 is an inhaled drug for the treatment of Covid-19.

Current stock price: 36.50 pence, up 37% on Monday

12-month change: down 64%

Copyright 2022 Alliance News Limited. All Rights Reserved.